Építés alatt – nem éles oldal
Belépés
Résztvevőt keres4. fázis

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
4. fázis
Résztvevők
224 fő, tervezett
Kezdés
2020. aug. 10.
Várható befejezés
2030. aug. 10.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • eltrombopag combining rituximab
  • eltrombopag
A regiszteradat frissítve
2026. április 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. Their ITP did not respond to earlier treatment or came back after it.

Életkor
18 to 60 years
Nem
All sexes
A betegség stádiuma
Primary ITP with a platelet count of <30 ×10^9/L on Day 1 (or within 48 hours before the first dose).
Korábbi kezelés
People must have had no response, or a relapse, after spleen removal (at least more than 6 months before), or after one or more earlier therapies. Earlier therapies such as corticosteroid, azathioprine, danazol, cyclosporin A or mycophenolate mofetil must be finished before joining, or their dose must not be raised after joining.
Biomarker vagy leletérték
Platelet count <30 ×10^9/L. Hemoglobin of at least 10.0 g/dl. Absolute neutrophil count ≥1500/µL (1.5×109/L). Clotting, liver and kidney tests near normal.

A részvétel fő kizáró okai

  • Any past blood clot in an artery or vein, with risk factors such as cancer, Factor V Leiden, ATIII deficiency or antiphospholipid syndrome
  • Heart disease in the last 3 months, or heart rhythm problems that raise clot risk
  • Pregnant or breastfeeding women
  • HIV infection, hepatitis C, or chronic or active hepatitis B
  • Infection in the last 1 months, or taking another study medicine now

A regiszter feltételei, szó szerint

Mind a 19 feltétel megnézéseKevesebb

Ki vehet részt

  • Signed written informed consent
  • Age from 18 to 60 years old
  • Diagnosed with ITP and have a platelet count of <30 ×10\^9/L on Day 1 (or within 48 hours prior to dosing on Day 1)
  • Patients who have no response or relapsed after splenectomy(at least more than 6 months). Or patients who have not been splenectomised and have either not responded to one or more prior therapies, or who have relapsed prior therapy
  • Subjects treated with previous therapy(including but not limited to corticosteroid, azathioprine, danazol, cyclosporin A, mycophenolate mofetil) must have been completed prior to randomization, or must not be increasing a dose after enrollment
  • No pre-existing cardiac disease within the last 3 months. No arrhythmia known to increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a Corrected QT interval (QTc) >450msec or QTc >480 for patients with a Bundle Branch Block
  • No pre-existing infection within the last 1 months(including but not limited to pulmonary infection)
  • Laboratory tests for coagulation function showed that prothrombin time (PT/INR) and activated partial thromboplastin time (APTT) no exceed normal by more than 20%. No history of clotting disorder, other than ITP
  • White blood cell count, neutrophil absolute value, hemoglobin, within the reference range, with the following exceptions:; Hemoglobin: females and males 10.0 g/dl are eligible for inclusion,; Absolute neutrophil count (ANC) ≥1500/µL (1.5×109/L) is required for inclusion
  • The following blood chemistry test result no exceed normal by more than 20%:alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine,serum albumin must not be below the lower limit of normal (LLN) by more than 10%
  • Subject is non-childbearing potential of childbearing potential and use acceptable methods of contraception throughout the study
  • Subjects fully understand and are able to comply with the requirements of the research protocol and are willing to complete the study as planned

Ki nem vehet részt

  • Patients with any prior history of arterial or venous thrombosis, and with following risk factors: cancer, Factor V Leiden, ATIII deficiency, antiphospholipid syndrome
  • Subjects is currently receiving treatment with another study medication
  • Any laboratory or clinical evidence for HIV infection
  • Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subject screening. Laboratory test shows positive serology for Hepatitis C or Hepatitis B (HB). In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded
  • History of platelet aggregation that prevents reliable measurement of platelet counts
  • Pregnant or lactating women
  • Any clinically relevant abnormality, other than ITP,which in the opinion of the investigator makes the subject unsuitable for participation in the study

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 60 év között vagy?

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This multicenter randomized, open-label study aimed to compare the efficacy and safety of eltrombopag combining rituximab with eltrombopag in China adult ITP patients .This study was be conducted in adult ITP patients who had not responded to or had relapsed after previous treatment of ITP, including first line therapy and /or splenectomy.

A vizsgálat 2 csoportja

  • efficacy of eltrombopag combining rituximabA vizsgált kezelés

    After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L. All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment. Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

    Kezelés: eltrombopag combining rituximab

  • efficacy of eltrombopagMár használt kezelés, összehasonlításként

    After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L. Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

    Kezelés: eltrombopag

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combining Rituximab With Eltrombopag In Adult ITP Patients
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT04518475: ki vehet részt
A regiszteradat frissítve
2026. április 29.